Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
The FDA’s big gamble on the new Alzheimer’s drug
+Practice
In print
Analysis
The FDA’s big gamble on the new Alzheimer’s drug
Tuesday 22 June 2021, 01:41 PM

Do the benefits of approving a drug before confirming it works outweigh the potential costs?
by C. Michael White, distinguished professor and head of the Department of Pharmacy Practice, University of Connecticut
The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated app
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.